Increased surfactant protein D in rat airway goblet and Clara cells during ovalbumin‐induced allergic airway inflammation
- 19 August 2002
- journal article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 32 (8) , 1251-1258
- https://doi.org/10.1046/j.1365-2745.2002.01423.x
Abstract
Structural remodelling of airways in asthma that follows inflammation may be affected by surfactant protein D (SP-D)-mediated effects on the immune response. To determine potential sites of SP-D interaction with the pulmonary immune response, we examined the distribution of immunoreactive SP-D in an experimental model of allergen-induced airway inflammation using immunohistochemistry, biochemical methods and in situ hybridization. The experimental model used subcutaneous injection of ovalbumin in adult rats, which induced an airway response to inhaled nebulized ovalbumin. Three groups of rats (ovalbumin, ovalbumin + dexamethasone and saline) were challenged thrice weekly for 3 weeks. A fourth group of seven rats (naive) were taken from the same delivery of rats as the other groups. Lungs were then lavaged to determine total cell count, eosinophil count, ovalbumin-specific IgE by enzyme-linked immunosorbent assay and SP-D by immunoblot. Tissue samples were fixed and embedded, and sections were studied for the infiltration of eosinophils and for expression of SP-D protein by histochemistry and mRNA by in situ hybridization. Ovalbumin induced perivascular and peribronchiolar eosinophilia which could be prevented by dexamethasone treatment. In addition, the ovalbumin-specific IgE levels in serum and bronchoalveolar lavage fluid of ovalbumin-challenged animals were enhanced. Increased amount of SP-D in lavage and tissue, particularly in type II pneumocytes, in Clara cells and, surprisingly, in hyperplastic goblet cells of inflamed lungs was found. SP-D mRNA was detected in goblet cells as well as in type II pneumocytes and Clara cells. Dexamethasone treatment did not affect level of SP-D immunoreactivity. SP-D accumulation is increased in this model of allergen-induced eosinophilia, both in upper and lower airways. The increase is unaffected by dexamethasone.Keywords
This publication has 31 references indexed in Scilit:
- Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergensJournal of Clinical Investigation, 2001
- Histopathology of the airway epithelium in an experimental dual-phase model of bronchial asthmaClinical and Experimental Allergy, 2001
- Histopathology of the airway epithelium in an experimental dual-phase model of bronchial asthmaClinical and Experimental Allergy, 2001
- Chronic allergen challenge as an experimental model: necessary, significant or useful?Clinical and Experimental Allergy, 2000
- Eotaxin Expression in Sephadex-Induced Lung Injury in RatsThe American Journal of Pathology, 1999
- Shifts in Lung Lymphocyte Profiles Correlate with the Sequential Development of Acute Allergic and Chronic Tolerant Stages in a Murine Asthma ModelThe American Journal of Pathology, 1999
- A RAT MODEL PRESENTING EOSINOPHILIA IN THE AIRWAYS, LUNG EOSINOPHIL ACTIVATION, AND PULMONARY HYPERREACTIVITYExperimental Lung Research, 1999
- Monoclonal Antibodies to Surfactant Protein D: Evaluation of Immunoreactivity in Normal Rat Lung and in a Radiation-Induced Fibrosis ModelExperimental Lung Research, 1995
- Pathology of asthma and its clinical implicationsJournal of Allergy and Clinical Immunology, 1993
- Pre- and postnatal stimulation of pulmonary surfactant protein D by in vivo dexamethasone treatment of ratsLife Sciences, 1992